Neurokinin-1 receptor activation in globus pallidus

Frontiers in Neuroscience

Volumn 1, Issue OCT, 2009, Pages

  Chen, Lei ^a,b   Cui, Qiao Ling ^a,b   Yung, Wing Ho ^a  

^a Prince of Wales Hospital   (Hong Kong)

^b QINGDAO UNIVERSITY   (China)

Author keywords

Globus pallidus; Neurokinin 1 receptor; Substance P

Indexed keywords

EID: 79960968283     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/neuro.23.002.2009     Document Type: Article

References (70)

1. Albin, R. L., Young, A. B., and Penney, J. B. (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375.
2. Aosaki, T., and Kawaguchi, Y. (1996). Actions of substance P on rat neostriatal neurons in vitro. J. Neurosci. 16, 5141-5153.
3. Arai, H., and Emson, P. C. (1986). Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system. Brain Res. 399, 240-249.
4. de Araujo, J. E., Huston, J. P., and Brandao, M. L. (1998). Aversive effects of the C-fragment of substance P in the dorsal periaqueductal gray matter. Exp. Brain Res. 123, 84-89.
5. Bailey, C. P., Maubach, K. A., and Jones, R. S. (2004). Neurokinin-1 receptors in the rat nucleus tractus solitarius: pre- and postsynaptic modulation of glutamate and GABA release. Neuroscience 127, 467-479.
6. Barbaresi, P. (1998). Immunocytochemical localization of substance P receptor in rat periaqueductal gray matter: a light and electron microscopic study. J. Comp. Neurol. 398, 473-490.
7. Barnes, J. M., Barnes, N. M., Costall, B., Cox, A. J., Domeney, A. M., Kelly, M. E., and Naylor, R. J. (1990). Neurochemical consequences following injection of the substance P analogue, DiMe-C7, into the rat ventral tegmental area. Pharmacol. Biochem. Behav. 37, 839-841.
8. Bell, M. I., Richardson, P. J., and Lee, K. (1998). Characterization of the mechanism of action of tachykinins in rat striatal cholinergic interneurons. Neuroscience 87, 649-658.
9. Bergman, H., Feingold, A., Nini, A., Raz, A., Slovin, H., Abeles, M., and Vaadia, E. (1998). Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci. 21, 32-38.
10. Betarbet, R., and Greenamyre, J. T. (2004). Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Exp. Neurol. 189, 393-403.
11. Boix, F., Mattioli, R., Adams, F., Huston, J. P., and Schwarting, R. K. (1992). Effects of substance P on extracellular dopamine in neostriatum and nucleus accumbens. Eur. J. Pharmacol. 216, 103-107.
12. Chen, L. W., Cao, R., Liu, H. L., Ju, G., and Chan, Y. S. (2003). The striatal GABAergic neurons expressing substance P receptors in the basal ganglia of mice. Neuroscience 119, 919-925.
13. Chesselet, M. F., and Delfs, J. M. (1996). Basal ganglia and movement disorders: an update. Trends Neurosci. 19, 417-422.
14. Chevalier, G., and Deniau, J. M. (1990). Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci. 13, 277-280.
15. Cui, Q. L., Yung, W. H., Xue, Y., and Chen, L. (2007). Substance P excites globus pallidus neurons in vivo. Eur. J. Neurosci. 26, 1853-1861.
16. Czeh, B., Simon, M., van der Hart, M. G., Schmelting, B., Hesselink, M. B., and Fuchs, E. (2005). Chronic stress decreases the number of parvalbumin-immunoreactive interneurons in the hippocampus: prevention by treatment with a substance P receptor (NK1) antagonist. Neuropsychopharmacology 30, 67-79.
17. De Ceballos, M. L., and Lopez-Lozano, J. J. (1999). Subgroups of parkinsonian patients differentiated by peptidergic immunostaining of caudate nucleus biopsies. Peptides 20, 249-257.
18. Fernandez, A., de Ceballos, M. L., Jenner, P., and Marsden, C. D. (1994). Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. Neuroscience 61, 73-79.
19. Fernandez, A., de Ceballos, M. L., Rose, S., Jenner, P., and Marsden, C. D. (1996). Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. Brain 119, 823-830.
20. Filion, M., and Tremblay, L. (1991). Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res. 547, 142-151.
21. Galarraga, E., Hernandez-Lopez, S., Tapia, D., Reyes, A., and Bargas, J. (1999). Action of substance P (neurokinin-1) receptor activation on rat neostriatal projection neurons. Synapse 33, 26-35.
22. Iwasaki, Y., Kinoshita, M., Ikeda, K., Takamiya, K., and Shiojima, T. (1989). Trophic effect of various neuropeptides on the cultured ventral spinal cord of rat embryo. Neurosci. Lett. 101, 316-320.
23. Jakab, R. L., and Goldman-Rakic, P. (1996). Presynaptic and postsynaptic subcellular localization of substance P receptor immunoreactivity in the neostriatum of the rat and rhesus monkey (Macaca mulatta). J. Comp. Neurol. 369, 125-136.
24. Jenner, P. (1995). The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 45, S6-S12.
25. Khan, S., Whelpton, R., and Michael-Titus, A. T. (1996). Evidence for modulatory effects of substance P fragments (1-4) and (8-11) on endogenous dopamine outflow in rat striatal slices. Neurosci. Lett. 205, 33-36.
26. Kombian, S. B., Ananthalakshmi, K. V., Parvathy, S. S., and Matowe, W. C. (2003a). Dopamine and adenosine mediate substance P-induced depression of evoked IPSCs in the rat nucleus accumbens in vitro. Eur. J. Neurosci. 18, 303-311.
27. Kombian, S. B., Ananthalakshmi, K. V., Parvathy, S. S., and Matowe, W. C. (2003b). Substance P depresses excitatory synaptic transmission in the nucleus accumbens through dopaminergic and purinergic mechanism. J. Neurophysiol. 89, 728-737.
28. Krasnova, I. N., Bychkov, E. R., Lioudyno, V. I., Zubareva, O. E., and Dambinova, S. A. (2000). Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats. Neuroscience 95, 113-117.
29. Lastres-Becker, I., Gomez, M., De Miguel, R., Ramos, J. A., and Fernandez-Ruiz, J. (2002). Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease. Neurotox. Res. 4, 601-608.
30. Li, Y. W., and Guyenet, P. G. (1997). C1 and other bulbospinal cells of the RVLM in neonatal rats. Am. J. Physiol. 273, R805-R813.
31. Liu, R., Ding, Y., and Aghajanian G. K. (2002). Beurokinins activate local glutamatergic inputs to serotonergic neurons of the dorsal raphe nucleus. Neuropsychopharmacology 27, 329-340.
32. Magill, P. J., Bolam, J. P., and Bevan, M. D. (2001). Dopamine regulates the impact of the cerebral cortex on the subthalamic nucleus-globus pallidus network. Neuroscience 106, 313-330.
33. Mantyh, P. W., Hunt, S. P., and Maggio, J. E. (1984). Substance P receptors: localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand. Brain Res. 307, 147-165.
34. Martorana, A., Fusco, F. R., D'Angelo, V., Sancesario, G., and Bernardi, G. (2003). Enkephalin, neurotensin, and substance P immunoreactivite neurones of the rat GP following 6-hydroxydopamine lesion of the substantia nigra. Exp. Neurol. 183, 311-319.
35. Mattioli, R., Schwarting, R. K., and Huston, J. P. (1992). Recovery from unilateral 6-hydroxydopamine lesion of substantia nigra promoted by the neurotachykinin substance P 1-11. Neuroscience 48, 595-605.
36. Maubach, K. A., Martin, K., Smith, D. W., Hewson, L., Frankshun, R. A., Harrison, T., and Seabrook, G. R. (2001). Substance P stimulates inhibitory synaptic transmission in the guinea pig basolateral amygdale in vitro. Neuropharmacology 40, 806-817.
37. Minabe, Y., Emori, K., Toor, A., Stutzmann, G. E., and Ashby, C. R. Jr. (1996). The effect of the acute and chronic administration of CP 96,345, a selective neurokinin1 receptor antagonist, on midbrain dopamine neurons in the rat: a single unit, extracellular recording study. Synapse 22, 35-45.
38. Mitrovic, I., and Napier, T. C. (1998). Substance P attenuates and DAMGO potentiates amygdala glutamatergic neurotransmission within the ventral pallidum. Brain Res. 792, 193-206.
39. Monteau, R., Ptak, K., Broquere, N., and Hilaire, G. (1996). Tachykinins and central respiratory activity: an in vitro study on the newborn rat. Eur. J. Pharmacol. 314, 41-50.
40. Mounir, S., and Parent, A. (2002). The expression of neurokinin-1 receptor at striatal and pallidal levels in normal human brain. Neurosci. Res. 44, 71-81.
41. Napier, T. C., Mitrovic, I., Churchill, L., Klitenick, M. A., Lu, X. Y., and Kalivas, P. W. (1995). Substance P in the ventral pallidum: projection from the ventral striatum, and electrophysiological and behavioral consequences of pallidal substance P. Neuroscience 69, 59-70.
42. Nikolaus, S., Huston, J. P., Korber, B., Thiel, C., and Schwarting, R. K. (1997). Pretreatment with neurokinin substance P but not with cholecystokinin-8S can alleviate functional deficits of partial nigrostriatal 6-hydroxydopamine lesion. Peptides 18, 1161-1168.
43. Nikolaus, S., Huston, J. P., and Schwarting, R. K. (1999). Pretreatment with fragments of substance-P or with cholecystokinin differentially affects recovery from sub-total nigrostriatal 6-hydroxydopamine lesion. Neural Plast. 6, 77-89.
44. Norris, S. K., Boden, P. R., and Woodruff, G. N. (1993). Agonists selective for tachykinin NK1 and NK3 receptors excite subpopulations of neurons in the rat medial habenula nucleus in vitro. Eur. J. Pharmacol. 234, 223-228.
45. Perez-Otano, I., Luquin, M. R., Oset, C., Herrero, M. T., Kupsch, A., Oertel, W., Obeso, J. A., and Del Rio, J. (1995). Neurotoxicity induced by prenatal exposure to MPTP on the monoaminergic and peptidergic systems of the marmoset brain. Exp. Neurol. 131, 108-113.
46. Pezzoli, G., Panerai, A. E., Di Giulio, A., Longo, A., Passerini, D., and Carenzi, A. (1984). Methionine-enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patients. Neurology 34, 516-519.
47. Plenz, D., and Kital, S. T. (1999). A basal ganglia pacemaker formed by the subthalamic nucleus and external globus pallidus. Nature 400, 677-682.
48. Preston, Z., Lee, K., Widdowson, L., Richardson, P. J., and Pinnock, R. D. (2000). Tachykinins increase [3H]acetylcholine release in mouse striatum through multiple receptor subtypes. Neuroscience 95, 367-376.
49. Ptak, K., Konrad, M., Di Pasquale, E., Tell, F., Hilaire, G., and Monteau, R. (2000). Cellular and synaptic effect of substance P on neonatal phrenic motoneurons. Eur. J. Neurosci. 12, 126-138.
50. Reid, M. S., Herrera-Marschitz, M., Hokfelt, T., Ohlin, M., Valentino, K. L., and Ungerstedt, U. (1990). Effects of intranigral substance P and neurokinin A on striatal dopamine release-I. Interactions with substance P antagonists. Neuroscience 36, 643-658.
51. Rioux, L., and Joyce, J. N. (1993). Substance P receptors are differentially affected in Parkinson's and Alzheimer's disease. J. Neural Transm. Park. Dis. Dement. Sect. 6, 199-210.
52. Rosler, N., Wichart, I., and Jellinger, K. A. (2001). Ex vivo lumbar and post mortem ventricular cerebrospinal fluid substance P-immunoreactivity in Alzheimer's disease patients. Neurosci. Lett. 299, 117-120.
53. Salin, P., Hajji, M. D., and Kerkerian-le Goff, L. (1996). Bilateral 6-hydroxydopamine-induced lesion of the nigrostriatal dopamine pathway reproduces the effects of unilateral lesion on substance P but not on enkephalin expression in rat basal ganglia. Eur. J. Neurosci. 8, 1746-1757.
54. Sanberg, P. R., Emerich, D. F., Aebischer, P., Amisetti, S. M., Ouellette, W., Koutouzis, T. K., Cahill, D. W., and Norman, A. B. (1993). Substance P containing polymer implants protect against striatal excitotoxicity. Brain Res. 628, 327-329.
55. Santarelli, L., and Saxe, M. D. (2003). Substance P antagonists: meet the new drugs, same as the old drugs? Insights from transgenic animal models. CNS Spectr. 8, 589-596.
56. Shen, K. Z., and North, R. A. (1992). Substance P opens cation channels and closes potassium channels in rat locus coeruleus neurons. Neuroscience 50, 345-353.
57. Shirakawa, T., and Moore, R. Y. (1994). Responses of rat suprachiasmatic nucleus neurons to substance P and glutamate in vitro. Brain Res. 642, 213-220.
58. Stacey, A. E., Woodhall, G. L., and Jones, R. S. (2002a). Activation of neurokinin-1 receptors promotes GABA release at synapses in the rat entorhinal cortex. Neuroscience 115, 575-586.
59. Stacey, A. E., Woodhall, G. L., and Jones, R. S. G. (2002b). Neurokinin-receptor-medicated depolarization of cortical neurons elicits an increase in glutamate release at excitatory synapses. Eur. J. Neurosci. 16, 1896-1906.
60. Stanfield, P. R., Nakajima, Y., and Yamaguchi, K. (1985). Substance P raises neuronal membrane excitability by reducing inward rectification. Nature 315, 498-501.
61. Tang, F., Cheung, A., and Vacca-Galloway, L. L. (1990). Measurement of neuropeptides in the brain and spinal cord of Wobbler mouse: a model for motoneuron disease. Brain Res. 518, 329-333.
62. Taylor, M. D., De Ceballos, M. L., Rose, S., Jenner, P., and Marsden, C. D. (1992). Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. Eur. J. Pharmacol. 219, 183-192.
63. Vacca-Galloway, L. L., and Steinberger, C. C. (1986). Substance P neurons sprout in the cervical spinal cord of the wobbler mouse: a model for motoneuron disease. J. Neurosci. Res. 16, 657-670.
64. Velumian, A. A., Zhang, L., Pennefather, P., and Carlen, P. L. (1997). Reversible inhibition of IK, IAHP, Ih and ICa currents by internally applied gluconate in rat hippocampal pyramidal neurones. Pflugers Arch. 433, 343-350.
65. Vergnano, A. M., Salio, C., and Merighi, A. (2004). NK1 receptor activation leads to enhancement of inhibitory neurotransmission in spinal substantia gelatinosa neurons of mouse. Pain 112, 37-47.
66. Wang, X., and Robertson, D. (1997). Effects of bioamines and peptides on neurones in the ventral nucleus of trapezoid body and rostral periolivary regions of the rat superior olivary complex: an in vitro investigation. Hear. Res. 106, 20-28.
67. Wang, X., and Robertson, D. (1998). Substance P-induced inward current in identified auditory efferent neurons in rat brain stem slices. J. Neurophysiol. 80, 218-229.
68. Wichmann, T., and DeLong, M. R. (1996). Functional and pathophysiological models of the basal ganglia. Curr. Opin. Neurobiol. 6, 751-758.
69. Yasuda, K., Robinson, D. M., Selvaratnam, S. R., Walsh, C. W., McMorland, A. J., and Funk, G. D. (2001). Modulation of hypoglossal motoneuron excitability by NK1 receptor activation in neonatal mice in vitro. J. Physiol. 534, 447-464.
70. Yung, K. K., Tang, F., Fielding, R., Du, Y. H., and Vacca-Galloway, L. L. (1992). Alteration in the levels of thyrotropin releasing hormone, substance P and enkephalins in the spinal cord, brainstem, hypothalamus and midbrain of the Wobbler mouse at different stages of the motoneuron disease. Neuroscience 50, 209-222.